logo
"It's not being looked at as a crazy thing": Emboldened Republicans renew push to restrict divorce

"It's not being looked at as a crazy thing": Emboldened Republicans renew push to restrict divorce

Yahoo20-02-2025

As the Trump administration continues its opening barrage of contentious executive actions targeting federal protections for marginalized Americans, legislators at the state level are taking another shot at no-fault divorce, renewing a heretofore quiet effort to turn a fringe idea — restricting Americans' ability to get a divorce — into a potential reality in the most conservative states.
In Oklahoma last month, a state senator introduced for the second time a bill seeking to remove "incompatibility" from the state's grounds for divorce, while also proposing a separate piece of legislation that would provide a tax credit to encourage covenant marriages, which make it harder for spouses to obtain a divorce. In Indiana, a now-dead bill introduced last month aimed to add a hurdle for married couples with minor children seeking a divorce on no-fault grounds.
The recent bills targeting no-fault divorce come against a backdrop of a slew of executive actions at the federal level that threaten civil rights and freedoms for a host of Americans. While these state bills have previously failed to gain any traction in their respective legislatures — Republican Oklahoma state Sen. Dusty Deevers' 2024 attempt at eliminating no-fault divorce failed to make it out of committee — their reappearances in state legislatures illuminates a potentially burgeoning trend toward further limiting women's rights.
In a post-Dobbs United States, legal experts find such a prospect alarming.
Marcia Zug, a professor of marital law at the University of South Carolina School of Law, told Salon that she expects more of this kind of legislation to arise in the years to come because of their spread. Despite these bills' current unpopularity, their failures are not dissuading lawmakers in other states from introducing similar proposals.
"It's not being looked at as a crazy thing," Zug said of some ultraconservative state lawmakers' approach to the legislation. "'Some state over there is doing it. Let's consider it, and maybe we want to propose it, and maybe it'll pass — maybe it won't.' But if more and more, states propose it, some state will pass it. Maybe other states will pass it. That's more likely than not at this point."
No-fault divorce laws allow for married couples to split without having to prove either spouse's fault at a trial. Often coupled with unilateral divorce, which provides that only one spouse has to file to begin the process, no-fault divorce provides greater ease in ending a marriage while keeping the already overwhelmed family court system from getting bogged down.
In 1969, then-California Governor Ronald Reagan's implementation of no-fault divorce set off a tidal wave of other states adopting "incompatibility" as divorce grounds over the following 20 years. Though it came alongside the expansion of women's social and political power during the second wave of feminism, no-fault divorce initially arose to defend the integrity of the family court system from fraud and perjury as spouses fabricated evidence of fault to prove they were entitled to a divorce.
Its modern-day opponents, which include men's rights activists and these bills' sponsors, argue that eliminating no-fault justification would in turn promote traditional families and values, reducing the risk of harming children with contentious divorce proceedings.
SB 829, the Oklahoma no-fault bill, is part of an eight-piece slate of proposals that Sen. Deevers claims will "restore moral sanity in Oklahoma." It would end no-fault divorce in the state while still allowing for splits in cases of "abandonment," including "habitual drunkenness" and "gross neglect of duty," "extreme cruelty," "adultery" and "unknown pregnancy." For couples with minor children, the bill would also require the at-fault parent to establish a trust fund accessible when the child reaches adulthood as a form of restitution for the divorce.
Alongside his proposal to eliminate no-fault divorce, Deevers introduced another bill offering a $2,500 tax credit as an incentive for opting into a covenant marriage, a restrictive marriage contract favored by right-wing Christian groups that creates barriers to divorce like required counseling and limits applicable divorce justifications. Only a few states offer covenant marriages — Louisiana, Arkansas and Arizona — and they are widely unpopular.
Zug said the bill's "extreme cruelty" grounds is what most alarmed her because of its vagueness and implication that non-extreme cruelty would be insufficient grounds for divorce.
"One of the worries of getting rid of no-fault divorce is that it will increase domestic violence because lots of people who get divorced under no-fault theoretically would have grounds because they're abused," she said. "But there's so many problems with trying to get a divorce based on physical cruelty that people don't. So here, not only would they have to go through all of that, they would have to show that it is extreme — and what does that mean?"
Marilyn Chinitz, a veteran divorce attorney at Blank Rome in New York, flagged Deevers' no-fault bill as especially problematic when paired with the covenant marriage incentive.
"In my view, the state is totally overstepping its bounds" in proposing such legislation, she said. "Whether you have kids or not, you should have the same right to get divorced. There shouldn't be any burden or hurdles for you to end the marriage," she added.
Neither a spokesman for Deevers nor the senator himself responded to requests for comment.
Deevers, in a January press release announcing the bills, argued that the no-fault bill elevates the profile of marriage by making it meaningful and a binding contract while protecting people's right to leave abusive spouses.
'A society that teaches and allows a marriage covenant to be less important and binding than a business contract will reap the fruit of social upheaval, unfettered dishonesty, crime, violence towards women, war on men, and expendability of children," he said.
Indiana state Rep. Timothy Wesco also stressed the impact of divorce on children though he only attempted to complicate no-fault divorce for married couples with minor children. Under his now-defunct bill, at least one of the parties seeking a divorce on "irretrievable breakdown" grounds would have to present a witness who could testify to affirm the breakdown. The legislation also placed limits on who that witness could be, naming as acceptable individuals an officiant of the marriage, a parent or sibling of the party, and a religious leader with knowledge of the marriage among others.
Unlike the Oklahoma proposal, the Indiana bill was trying to implement a "speed bump," argued Zug. The assumption behind it, she said, is that "if you have to bring in a third party to agree with you that this marriage is one that can't be saved, you're less likely to divorce."
While she said she doesn't find that assumption "likely to be true," she added that the bill could be a step toward further attacking no-fault justification in the future.
However, Joanna Grossman, an SMU Dedman School of Law professor of family law, said that despite Wesco's possible intention, in practice, his bill would have been unlikely to have any tangible impact on the divorce process. If ever implemented, divorces would likely proceed exactly as they currently do with the addition of a third party who submits an affidavit to attest to the grounds.
"This rule only applies in the divorce that's on a no-fault ground, and so they're testifying to nothing," she told Salon. "They're testifying that the person who filed for divorce thinks the marriage is over. It's not an objective fact."
The Indiana House voted to withdraw Wesco's bill a week after it was filed in late January because its introduction violated the legislature's rules governing how many proposals a lawmaker can submit during one legislative session. While dead this session, the bill could theoretically return to the state legislature.
Salon asked a spokesperson for Wesco whether the lawmaker had plans to reintroduce the bill or similar legislation. That spokesperson told Salon he'd pass the questions on to the Indiana representative. Wesco did not respond by late Tuesday afternoon.
Wesco said in a late January post to X that he introduced the bill after watching parents "casually getting divorced and ruining their kids' lives while mutually claiming their marriage was irretrievably broken."
Chinitz argued, however, that these kinds of bills would have a similar effect on children and fail to protect children in the way they set out to. Increasing the time spent in a "vulnerable situation" with parents in an unhappy marriage "could be very dangerous for them and for their kids," she said.
"It's dangerous, and it has tremendous negative and adverse impact," Chinitz said of legislation targeting no-fault. "I think it's going to be very costly — costly, financially and costly because it's going to force people to stay in dangerous situations. Let's face it, victims will be less likely to report domestic violence, and it prolongs the divorce process — what a terrible impact that has on children."
Deevers' and Wesco's bills are far from the first proposals taking aim at no-fault divorce laws.
Deevers' first introduced legislation attempting to strike "incompatibility" from the state's divorce grounds in 2024, and a Republican state representative in South Dakota, Tony Randolph, introduced a similar bill every year between 2020 and 2024. The GOP in other states have also voiced an interest in legislation restricting or cutting no-fault divorce grounds, with Republican parties in Texas and Nebraska including guidance for potential legislation in their most recent platforms.
These bills, should they ever be successful, threaten to ensnare people in abusive and violent relationships while disproportionately limiting low-income Americans' access to divorce, argued Katie Dilks, the executive director of advocacy organization Oklahoma Access to Justice.
"When we look at this pitch to reduce divorce rates, it's really displaying a lack of understanding of what the actual causes and contributors are to Oklahoma's high divorce rates, which is unsafe families and unsustainable living conditions," Dilks said of Deevers' bill in a phone interview.
Oklahoma, which has one of the highest divorce rates in the nation, also has some of the country's highest rates of intimate partner violence and domestic violence homicides. Oklahomans also face procedural and legal barriers to obtaining divorces such as a lack of standardized court forms, Dilks noted.
"If we were to move to a system that required proving fault and having a full evidentiary trial, it would be a significant burden both on our courts but also on Oklahomans who need access to this to stay safe," Dilks said.
Dilks and Grossman said that in the current political climate, they don't expect these bills to gain any serious traction in state legislatures. While Dilks said the Trump administration may act as a sort of tailwind for rightwing lawmakers pursuing this legislation, she's unsure if it will "fundamentally change the paths and outcomes of those bills."
"I think it's just standard issue conservatism misogyny. There's nothing special about these bills," Grossman added. "They seem to be consistent with people who either want to take symbolic actions that shore up their conservative bona fides, or they actually want to trap women in marriages."
She also argued that the level of social disruption wrought by the current administration's actions makes it less likely these types of legislation will advance seriously because, by comparison, they may appear as "petty distractions."
"At the same time, maybe the big picture distraction will mean that people really can't pay attention to the small things that actually will cause a lot of harm and are just not going to get the attention they deserve from opponents," she said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Patents and economies of scale support Pfizer's wide moat
Patents and economies of scale support Pfizer's wide moat

Yahoo

time31 minutes ago

  • Yahoo

Patents and economies of scale support Pfizer's wide moat

Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and Mylan. With fewer older medications and fewer patent losses, Pfizer is well-positioned for consistent growth, excluding the erratic sales of Covid-19-related products. The company is less vulnerable to any one patent loss thanks to its wide range of medications. Because of its more complex manufacturing process and more affordable prices, Pfizer's stronger position in the vaccine marketwhich includes the pneumococcal vaccine Prevnarmakes it more resilient to generic competition. Warning! GuruFocus has detected 6 Warning Signs with PFE. With a 30% to 80% reduction, Trump's executive order would establish a "most favored nation" policy in which the US would pay the same amount for prescription medications as the nation with the lowest price. It is anticipated that this policy, which was previously blocked by courts, will reduce the US's annual drug spending of over $400 billion, saving taxpayers over a seven-year period. Given that drug prices in the United States are high when compared to other countries, Pfizer's U.S. revenue could be drastically impacted by the 30% to 80% price cut, especially for high-margin medications. International reference pricing policies have long been opposed by the pharmaceutical industry, which claims they could hinder innovation and limit access to new companies anticipate that the order will target Medicare and may have an impact on medications not covered by Biden's Inflation Reduction Act. President Trump has said that significant tariffs on pharmaceutical products will probably be announced soon. He has also put a 90-day hold on broader tariffs for the majority of his trading partners to give them time to negotiate. Despite being mostly exempt from tariffs, the biopharma industry is preparing for a possible pharma-specific announcement that might affect global manufacturing strategies. Products made in Europe and imported into the US may be subject to the rumored 25% tariff, necessitating the construction of new facilities that will take years to complete. Due to home country manufacturing, tax benefits, lower production costs, and exposure to currency fluctuations, businesses based in the US and Europe are heavily exposed to European manufacturing. Because drug spending is not cyclical, the direct effect of tariffs on earnings is probably going to be minimal, and the indirect effect of a possible recession should also be minimal. With the exception of small-scale US capacity expansions, biopharma is unlikely to completely reevaluate its manufacturing footprint if pharmaceutical tariffs are implemented but are lifted after 2026 as a result of political pressure from the midterm elections. Leadership in Vaccines Pfizer stands out with its dominant position in vaccines, most notably its highly successful COVID-19 vaccine developed in partnership with BioNTech. This vaccine not only generated significant revenue but also established Pfizer as a leader in mRNA technology, a platform with potential applications in oncology, rare diseases, and beyond. Johnson & Johnson (J&J): J&J also developed a COVID-19 vaccine, but it was less widely adopted due to lower efficacy rates and safety concerns, giving Pfizer a clear advantage in this high-impact area. GlaxoSmithKline (GSK): GSK has a strong vaccine portfolio (e.g., shingles and meningitis vaccines) but did not independently develop a COVID-19 vaccine, relying on partnerships like Sanofi, which delayed its entry and diminished its competitive stance. Bristol Myers Squibb (BMS): BMS has no significant presence in vaccines, focusing instead on oncology and immunology, making Pfizer's vaccine leadership a unique strength. R&D Capabilities and Pipeline Focus Pfizer's R&D efforts are concentrated on high-growth therapeutic areas such as oncology, vaccines, and rare diseases. Its ability to leverage mRNA technology and rapidly develop innovative therapies underscores its R&D prowess. J&J: J&J's R&D spans pharmaceuticals, medical devices, and consumer health. While this diversification provides stability, it may dilute J&J's focus on cutting-edge pharmaceutical innovation compared to Pfizer's targeted approach. GSK: GSK excels in respiratory diseases and HIV research, but its pipeline is less broad and lacks the same level of innovation in emerging technologies like mRNA that Pfizer is advancing. BMS: BMS has a strong oncology pipeline, particularly in immuno-oncology, but its narrower focus limits its competitiveness in other high-growth areas where Pfizer thrives, such as vaccines and rare diseases. Global Reach and Market Presence Pfizer operates in over 150 countries, giving it a vast global footprint that enhances its ability to distribute products and capture market share across both developed and emerging markets. J&J: J&J also has a global presence, but its focus is split across pharmaceuticals, medical devices, and consumer health, potentially reducing its pharmaceutical market penetration compared to Pfizer. GSK: GSK is strong in Europe and emerging markets but less dominant in the U.S., the world's largest pharmaceutical market, where Pfizer has a significant advantage. BMS: BMS focuses heavily on the U.S. and Europe, with less presence in emerging markets, limiting its global scale compared to Pfizer. Brand Reputation and Trust The success of Pfizer's COVID-19 vaccine has significantly boosted its brand recognition and trust among consumers, healthcare providers, and governments, reinforcing its market position. J&J: J&J enjoys a strong reputation in consumer health, but its pharmaceutical division lacks the same level of visibility and trust as Pfizer's, particularly after COVID-19 vaccine challenges. GSK: GSK is well-regarded in respiratory and HIV treatments but does not have the broad public recognition that Pfizer has achieved. BMS: BMS is respected in oncology but lacks the widespread brand prominence that Pfizer has cultivated. Innovation in Emerging Technologies Pfizer's investment in mRNA technology positions it as a pioneer in pharmaceutical innovation, with potential applications in vaccines, cancer treatments, and more, giving it a forward-looking edge. J&J: J&J innovates in medical devices and consumer health but trails Pfizer in adopting next-generation pharmaceutical technologies like mRNA. GSK: GSK focuses on innovation in respiratory and HIV treatments but has not made significant advances in mRNA or other emerging platforms. BMS: BMS drives innovation in immuno-oncology but lacks Pfizer's breadth and leadership in cutting-edge technologies. Pfizer's competitive edge over Johnson & Johnson, GlaxoSmithKline, and Bristol Myers Squibb lies in its unmatched leadership in vaccines, particularly through mRNA technology, combined with a robust R&D pipeline, extensive global reach, substantial financial resources, strong brand reputation, and a focus on innovation. While J&J benefits from diversification, GSK from efficiency, and BMS from oncology expertise, none rival Pfizer's comprehensive strengths across these critical areas, ensuring its dominance in the pharmaceutical landscape. Pfizer's broad moat is supported by patents, economies of scale, and a strong distribution network. Strong pricing power derived from Pfizer's patent-protected medications allows the company to produce returns on investment that exceed its cost of capital. The company can develop the next generation of drugs before generic competition appears thanks to the patents. Furthermore, even though Pfizer has a wide range of products, there is some product concentration, as Prevnar accounts for slightly more than 10% of total sales (not including sales of the COVID-19 vaccine).However, because of the vaccine's complicated manufacturing process and comparatively low cost, we don't anticipate typical generic competition. Ibrance and Eliquis each account for nearly 10% of sales. On the other hand, we anticipate that new products will eventually lessen the competition from generic versions of important medications. In order to lessen the pressure on margins from lost sales of high-margin drugs, Pfizer's operating structure permits cost-cutting after patent losses. All things considered, Pfizer's well-established product line generates the massive cash flows required to cover the typical $800 million in development expenses for each new medication. For smaller pharmaceutical companies without Pfizer's resources, the company's robust distribution network positions it as a solid partner. On April 15, President Donald Trump issued an executive order outlining possible policy changes intended to reduce the cost of pharmaceuticals in the United States. The biopharma industry is looking forward to these changes because they have the potential to either help or hurt innovation. In the worst situation, international price benchmarks have the potential to drastically cut US drug prices and lessen financial incentives for international drug development. On the plus side, eliminating the "pill penalty" that only grants small molecule medications nine years of Medicare negotiation protection may promote innovation across all treatment modalities. Trump's executive order may have a positive or negative impact on the industry, but it has no effect on valuations or uncertainty ratings. The protection period is not specified in Trump's request that US Department of Health and Human Services Secretary Robert F. Kennedy Jr. collaborate with Congress to address the pill penalty, which is contingent upon Congressional action. Since innovation and a favorable mergers and acquisitions climate support long-term pricing power and offset possible short-term tariff pressure, rising tax rates, and approval delays, the biopharma industry seems undervalued. Due to liver damage in a clinical trial, Pfizer has announced the discontinuation of danuglipron, an oral small molecule GLP-1 agonist. In the anticipated $200 billion global GLP-1 market by 2031, the company sought to provide a potential second-to-market oral small molecule GLP-1 agonist, behind Lilly's orforglipron. Clinical trial failures and declining demand for Pfizer's COVID vaccine and antiviral medication have hurt the company's growth. Because of its diverse pipeline and portfolio, Pfizer is expected to have a wide-moat case, protecting it from the effects of individual program failures, especially those involving high-risk programs like danuglipron. Other medication candidates might benefit from Pfizer's objective of turning danuglipron into a once-daily business could use its $15 billion acquisition budget to fund the development of more sophisticated medication candidates. Efforts in Genetic Engineering: A solid growth driver for Pfizer is the strong pipeline of innovative treatment options, especially in oncology and immunology, which take the leap with cutting-edge scientific technology. To be more specific, Pfizer's resource allocation to immuno-oncology is evident, developing of checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) and chimeric antigen receptor T-cell (CAR-T) therapies. For instance, this method of treatment mitigates the immune system's ability to detect and destroy the specified cancer cells by varying the immune system response or, in some cases, by using specially modified T-cells that can identify the particular antigens on tumors that are solely expressed in those particular tumors, which are in question. This is the area of advancement where Pfizer has outdone the rest as they are perfecting monoclonal antibody formatsdesigning them in a way that they will bind more tightly and specifically to targets using protein engineeringand they are also testing out bispecific antibodies that trigger switches at two targets, therefore enhancing healing by more than one method. The pipeline is further supported by vast R&D investment in gene therapy and precision medicine, which utilize adeno-associated virus (AAV) vector platforms for gene delivery and next-generation sequencing for actionable mutation identification respectively. These endeavors are aimed at enhancing the overall patient health and market potential of the drugs by changing the treatment convention from testing a wide spectrum to one that is genotype-driven. Clinical trials are usually designed in a way to be fast-tracked so that they can move quickly to the next stage of development. By focusing on such advanced technologies, Pfizer is embarking on capturing a large section of the market with high-growth therapeutic branches, thus gaining revenue through innovation guided by complex disease biology. Revenue Growth: The launching of these high-value treatments is expected to increase revenue as well as drive down costs for Pfizer. Most of the drugs that are released in the onco-immunology field possess a technical edge and therapeutic effectiveness, therefore, these new treatements often demand high price. These drugs are capable of pumping up profits significantly once they clear regulatory hurdles and find their way onto the market. take the example of just-above successful immuno-oncology drug sales, which always have brisk selling and marvelous sales. In addition, Pfizer can speed-up the whole clinical process with something like adaptive trial designs, this process will be quicker and thus benefits are obtained faster from the new products. Impact on profitability The weight on profitability depends on the ratio of costs and returns. What is actually known is that lamas like the checkpoint inhibitors and CAR-T treatments that are so good require a lot of investment in R&D. But there is an inherent advantage for these drugs thanks to their patent protection that comes with market exclusivity, which in turn, allows Pfizer to keep its pricing strategy stick and generate very high profits. Success in the selling of the product along the lines of this new dimension along with the efficiency of producing more could prove to be the road to better profitability. However, there are barriers such as competition from other drug companies plus the worry of the price cuts from payers that can erode this success. So if Pfizer is able to eliminate the competition and stays ahead in the game by reducing costs as well, these high markups brought about by the introduction of such innovative drugs should positively affect the total profitability of the company. Generic competition, possible changes to government drug pricing policies, the more stringent FDA, and more powerful managed-care and pharmacy benefit managers present Pfizer with difficulties in drug development. In some disease areas, developing new drugs is getting harder, and pharmacy benefit managers and managed-care organizations have grown to be strong players with the ability to bargain for cheaper drug costs. Nearly one-fourth of the company's total sales are generated by its medications, Eliquis, Ibrance, and Xtandi, and they are heavily exposed to the Medicare channel. Given that Pfizer's product portfolio is less vulnerable to potential litigation, the company's base-case annual legal costs, assuming a 50% probability of future costs associated with product governance ESG risks, come close to 1% of non-GAAP net income. Pfizer's valuation multiples highlights their strong financial position and potential undervaluation. Their P/E Non-GAAP ratios7.61 (FY1), 7.42 (FY2), and 7.44 (FY3)are lower than JNJ's 14.00 (FY1) and SNY's 10.80 (FY1), suggesting investors may undervalue our earnings potential. The PEG Non-GAAP (FWD) of 1.49 is competitive, higher than SNY's 0.76 but below JNJ's 1.70, reflecting moderate growth prospects. Pfizer's EV/Sales (TTM) of 2.81 is more conservative than JNJ's 4.21, while the EV/EBITDA (FWD) of 7.13 compares favorably to JNJ's 11.45, indicating operational efficiency. The Price to Book (TTM) of 1.44 is significantly lower than JNJ's 5.23, and our Price to Cash Flow (TTM) of 9.29 beats JNJ's 15.67, underscoring robust cash flow generation. These metrics position Pfizer as a value opportunity among peers After the Seagen acquisition, Pfizer released its 2024 guidance, which included a $8 billion COVID-19 product guidance$5 billion less than anticipated. The business admitted that, excluding sales of COVID-19 products, it would not meet the prior growth-rate projection of 6% from 2020 to 2025. Pfizer reaffirmed its support for the dividend, which is regarded as safe and likely to boost stock valuation, despite the deteriorating outlook. Over the next ten years, the company anticipates steady sales as new products counteract older medications that are losing their patent protection. From the middle of 2023 to the end of 2024, Pfizer is anticipated to reduce operating expenses by $4 billion, which will aid the company in adjusting to the waning pandemic and declining sales of COVID-19 products. Growth could be accelerated through acquisitions, and future margin pressure could be reduced through restructuring initiatives. It is estimated that Pfizer's weighted average cost of capital is 7% and its cost of equity is 7.5%. Activist investor Jeffrey Smith's recent stake worth $407 million could presage the much needed turnarounds at Pfizer. Investors and shareholders can reasonably expect further cost-cuts and an efficient use of capital, leading to higher margins and free cashflow. This case could follow the path of Walt Disney, albeit with less drama, where Jeff Ubben of ValueAct had a pivotal role in Disney's turnaround campaign. The large-cap biopharma company Pfizer's debt size, business cyclicality, and debt maturity outlook all contribute to its sound balance sheet and low risk levels. To support opportunistic acquisitions and handle product litigation issues with little market concern, the company should have a strong enough balance sheet. Pfizer spends slightly less on R&D than the industry average, with a mid- to high-teens percentage of sales. Patent losses are offset by the company's robust pipeline of next-generation medications. The company's investment in cutting-edge new medications, mostly aimed at immunology and oncology, improves its standing and increases returns on capital. For biopharma companies in the sector, this balance sheet strength is essential. This article first appeared on GuruFocus. Sign in to access your portfolio

If You Were Cut Off For Not Supporting Trump, We Want To Hear Your Story
If You Were Cut Off For Not Supporting Trump, We Want To Hear Your Story

Yahoo

time33 minutes ago

  • Yahoo

If You Were Cut Off For Not Supporting Trump, We Want To Hear Your Story

America has become increasingly polarized in the last decade, and much of the blame, IMO, goes to one man: President Donald Trump. Trump's divisive policies and rhetoric have torn apart friendships, communities, and families. The cult-like behavior from many of his followers has led many people to cut off Trump supporters from their lives. This is something we've covered — but now we want to hear from people who themselves were cut off for not supporting Trump. Related: What Type Of Engagement Ring Is Perfect For You? Plan Your Wedding To Find Out Do you have a family member who stopped speaking to you because you did not vote for Donald Trump? Related: Which Sea Creature Are You? Order At A High-Class Restaurant To Find Out Maybe a friendship of many years ended because you disagreed about Trump's tariffs. Perhaps a partner even broke up with you because you pointed out misinformation or called out misogyny in the current administration. Whatever happened, we want to hear about it. Tell us who cut you off and how it went down in the comments below — or via this anonymous form — and you could be featured in an upcoming BuzzFeed Community post. Also in Community: Wanna Know Which Disney Princess Is Your 100% Personality Twin? Just Eat A Bunch Of Desserts To Find Out Also in Community: There Are 6 Universal Wedding Dress Aesthetics — Here's Your Best Fit Also in Community: I'll Be Really Impressed If You Can Get 15/15 On This Really Hard World Capital Quiz

Trump Uses Epstein's Lawyer as Human Shield Against Musk's ‘Really Big Bomb'
Trump Uses Epstein's Lawyer as Human Shield Against Musk's ‘Really Big Bomb'

Yahoo

time35 minutes ago

  • Yahoo

Trump Uses Epstein's Lawyer as Human Shield Against Musk's ‘Really Big Bomb'

President Donald Trump's previously long-standing relationship with New York financier and convicted sex offender Jeffrey Epstein has been brought under sharp scrutiny following the president's spectacular fallout with Elon Musk. During the once-tight pair's highly public bust-up on Thursday, Musk alleged on X that the reason the Epstein files have not been released as promised is because Trump is in them, describing it as 'the really big bomb.' In the first direct response to the allegation, Trump shared a post to Truth Social on Friday to reiterate his claim that there is nothing salacious about him in Epstein's law enforcement records. 'I can say authoritatively, unequivocally, and definitively that [Epstein] had no information to hurt President Trump. I specifically asked him!' wrote attorney David Schoen, who was hired to lead Epstein's defense shortly before his death in 2019. Trump shared the message to his followers on Truth Social. The White House has already responded to Musk's incendiary statement, describing the outburst as 'an unfortunate episode for Elon' and attributing the sudden vitriol to a clash over the policies contained within Trump's 'Big, Beautiful Bill.' The Trump administration has previously said that records relating to Epstein, including flight logs and other information, would be declassified, but that has yet to happen. Trump had a long, documented relationship with Epstein through the late 1980s to the early 2000s and appears in numerous photographs alongside him and his convicted partner, Ghislaine Maxwell. In a 2002 interview, Trump even praised Epstein as a 'terrific guy.' In 2017, Epstein described himself to author Michael Wolff as Trump's 'closest friend for 10 years,' although the pair appear to have had a falling out in the early 2000s. 'He's a horrible human being,' Epstein later said of the president in the same interview. When asked in 2024 if he would release a number of classified records relating to 9/11, the assassination of John F. Kennedy, and Epstein, Trump quickly agreed, before hedging over the Epstein files. 'I guess I would. I think that less so because, you don't know, you don't want to affect people's lives if it's phony stuff in there, because it's a lot of phony stuff with that whole world. But I think I would,' Trump said in a Fox News interview, this section of which was cut from the broadcast. Off the back of Musk's outburst, Democrats are now calling on Attorney General Pam Bondi to clarify the accusation and provide a timeline in which to declassify and release all records relating to Epstein. Trump has not been accused of any wrongdoing in relation to Epstein.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store